Literature DB >> 9343181

Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells.

A Valenzuela1, J Blanco, B Krust, R Franco, A G Hovanessian.   

Abstract

The CD4 molecule is an essential receptor for human immunodeficiency virus type 1 (HIV-1) through high-affinity interactions with the viral external envelope glycoprotein gp120. Previously, neutralizing monoclonal antibodies (MAbs) specific to the third hypervariable domain of gp120 (the V3 loop) have been thought to block HIV infection without affecting the binding of HIV particles to CD4-expressing human cells. However, here we demonstrate that this conclusion was not correct and was due to the use of soluble gp120 instead of HIV particles. Indeed, neutralizing anti-V3 loop MAbs inhibited completely the binding and entry of HIV particles into CD4+ human cells. In contrast, the binding of virus was only partially inhibited by neutralizing anti-CD4 MAbs against the gp120 binding site in CD4, which, like the anti-V3 loop MAbs, completely inhibited HIV entry and infection. Nonneutralizing control MAbs against either the V3 loop or the N or C terminus of gp120 had no significant effect on HIV binding and entry. HIV-1 particles were also found to bind human and murine cells expressing or not expressing the human CD4 molecule. Interestingly, the binding of HIV to CD4+ murine cells was inhibited by both anti-V3 and anti-CD4 MAbs, whereas the binding to human and murine CD4- cells was affected only by anti-V3 loop MAbs. The effect of anti-V3 loop neutralizing MAbs on the HIV binding to cells appears not to be the direct consequence of gp120 shedding from HIV particles or of a decreased affinity of CD4 or gp120 for binding to its surface counterpart. Taken together, our results suggest the existence of CD4-dependent and -independent binding events involved in the attachment of HIV particles to cells; in both of these events, the V3 loop plays a critical role. As murine cells lack the specific cofactor CXCR4 for HIV-1 entry, other cell surface molecules besides CD4 might be implicated in stable binding of HIV particles to cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9343181      PMCID: PMC192287     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding.

Authors:  U Olshevsky; E Helseth; C Furman; J Li; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

2.  Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS.

Authors:  B R Starcich; B H Hahn; G M Shaw; P D McNeely; S Modrow; H Wolf; E S Parks; W P Parks; S F Josephs; R C Gallo
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

3.  Identification of conserved and divergent domains within the envelope gene of the acquired immunodeficiency syndrome retrovirus.

Authors:  R L Willey; R A Rutledge; S Dias; T Folks; T Theodore; C E Buckler; M A Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Involvement of a leukocyte adhesion receptor (LFA-1) in HIV-induced syncytium formation.

Authors:  J E Hildreth; R J Orentas
Journal:  Science       Date:  1989-06-02       Impact factor: 47.728

6.  T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.

Authors:  D Klatzmann; E Champagne; S Chamaret; J Gruest; D Guetard; T Hercend; J C Gluckman; L Montagnier
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

7.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.

Authors:  A G Dalgleish; P C Beverley; P R Clapham; D H Crawford; M F Greaves; R A Weiss
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

8.  Monoclonal antibodies to an interferon-induced Mr 68,000 protein and their use for the detection of double-stranded RNA-dependent protein kinase in human cells.

Authors:  A G Laurent; B Krust; J Galabru; J Svab; A G Hovanessian
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

9.  Effects of anti-gp120 monoclonal antibodies on CD4 receptor binding by the env protein of human immunodeficiency virus type 1.

Authors:  P S Linsley; J A Ledbetter; E Kinney-Thomas; S L Hu
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

10.  Neutralizing monoclonal antibodies to the AIDS virus.

Authors:  E K Thomas; J N Weber; J McClure; P R Clapham; M C Singhal; M K Shriver; R A Weiss
Journal:  AIDS       Date:  1988-02       Impact factor: 4.177

View more
  14 in total

1.  High affinity CXCR4 inhibitors generated by linking low affinity peptides.

Authors:  Chaozai Zhang; Lina S Huang; Ruohan Zhu; Qian Meng; Siyu Zhu; Yan Xu; Huijun Zhang; Xiong Fang; Xingquan Zhang; Jiao Zhou; Robert T Schooley; Xiaohong Yang; Ziwei Huang; Jing An
Journal:  Eur J Med Chem       Date:  2019-04-01       Impact factor: 6.514

2.  Inhibition of coreceptor-independent cell-to-cell human immunodeficiency virus type 1 transmission by a CD4-immunoglobulin G2 fusion protein.

Authors:  Berta Bosch; Julià Blanco; Eduardo Pauls; Imma Clotet-Codina; Mercedes Armand-Ugón; Boyan Grigorov; Delphine Muriaux; Bonaventura Clotet; Jean-Luc Darlix; José A Esté
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

3.  Histone deacetylase 6 regulates human immunodeficiency virus type 1 infection.

Authors:  Agustín Valenzuela-Fernández; Susana Alvarez; Mónica Gordon-Alonso; Marta Barrero; Angeles Ursa; J Román Cabrero; Gerónimo Fernández; Salvador Naranjo-Suárez; Maria Yáñez-Mo; Juan M Serrador; M Angeles Muñoz-Fernández; Francisco Sánchez-Madrid
Journal:  Mol Biol Cell       Date:  2005-09-07       Impact factor: 4.138

4.  A Novel High-Throughput Screening Assay to Identify Inhibitors of HIV-1 gp120 Protein Interaction with DC-SIGN.

Authors:  Thuong H Tran; Rasha El Baz; Andrea Cuconati; James Arthos; Pooja Jain; Zafar K Khan
Journal:  J Antivir Antiretrovir       Date:  2011-10-17

5.  Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization.

Authors:  Jason Hammonds; Xuemin Chen; Timothy Fouts; Anthony DeVico; David Montefiori; Paul Spearman
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

6.  Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques.

Authors:  D C Montefiori; J T Safrit; S L Lydy; A P Barry; M Bilska; H T Vo; M Klein; J Tartaglia; H L Robinson; B Rovinski
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

7.  CD4-independent infection of two CD4(-)/CCR5(-)/CXCR4(+) pre-T-cell lines by human and simian immunodeficiency viruses.

Authors:  A Borsetti; C Parolin; B Ridolfi; L Sernicola; A Geraci; B Ensoli; F Titti
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

8.  Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope.

Authors:  N L Letvin; S Robinson; D Rohne; M K Axthelm; J W Fanton; M Bilska; T J Palker; H X Liao; B F Haynes; D C Montefiori
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

9.  Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: investigation of the mechanism of inhibition.

Authors:  C Spenlehauer; A Kirn; A M Aubertin; C Moog
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

10.  Initial binding of murine leukemia virus particles to cells does not require specific Env-receptor interaction.

Authors:  M Pizzato; S A Marlow; E D Blair; Y Takeuchi
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.